Spotlighting 3 Promising Penny Stocks With Over $90M Market Cap

Over the last 7 days, the United States market has dropped 1.6%, but it remains up 12% over the past year, with earnings forecasted to grow by 17% annually. Investing in penny stocks — a term that might seem outdated but still holds relevance — can provide access to growth opportunities typically found in smaller or newer companies. By focusing on those with solid financial health and potential for long-term growth, investors may uncover valuable opportunities within this niche market segment.

We'll examine a selection from our screener results.

KORU Medical Systems (KRMD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the drug delivery market in the U.S. and internationally, with a market cap of $138.52 million.

Operations: The company generates revenue of $45.11 million from its Surgical & Medical Equipment segment.

Market Cap: $138.52M

KORU Medical Systems has shown promising revenue growth, with recent quarterly sales increasing to US$12.05 million from US$10.19 million the previous year, and projected annual revenue between US$47.5 million and US$48.5 million for 2026. Despite being unprofitable, the company has reduced its losses over the past five years by 6% annually and maintains a strong cash runway exceeding three years due to positive free cash flow growth of 12.9% per year. KORU's financial stability is supported by short-term assets covering both short- and long-term liabilities, alongside a seasoned board of directors with an average tenure of 5.4 years.

• Dive into the specifics of KORU Medical Systems here with our thorough balance sheet health report.
• Review our growth performance report to gain insights into KORU Medical Systems' future.

Tilly's (TLYS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tilly's, Inc. is a specialty retailer in the United States offering casual apparel, footwear, accessories, and hardgoods for young men and women as well as boys and girls, with a market cap of $143.15 million.

Operations: The company generates revenue primarily from its retail apparel segment, amounting to $582.94 million.

Market Cap: $143.15M

Tilly's, Inc. has recently become profitable, reporting a net income of US$8.38 million for the second quarter of 2026, up from US$3.17 million the previous year, with sales reaching US$163.51 million. Despite a past decline in earnings by 56.9% annually over five years, Tilly's shows potential with no debt and short-term assets exceeding liabilities by US$22.1 million. The company expects third-quarter net sales between US$150 million and US$155 million with a projected net income of up to US$3.7 million, reflecting an anticipated comparable sales increase of up to 14%.

• Get an in-depth perspective on Tilly's performance by reading our balance sheet health report here.
• Explore Tilly's analyst forecasts in our growth report.

Crimson Wine Group (CWGL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Crimson Wine Group, Ltd. operates through its subsidiaries to produce and sell luxury wines in the United States, with a market cap of $90.37 million.

Operations: The company's revenue is primarily generated through wholesale channels, amounting to $43.66 million, and direct-to-consumer sales, which contribute $25.69 million.

Market Cap: $90.37M

Crimson Wine Group, Ltd. reported second-quarter sales of US$20.47 million, up from US$17 million a year ago, though it recorded a net loss of US$0.346 million. The company demonstrates financial stability with short-term assets totaling US$121.2 million exceeding both short and long-term liabilities significantly, but its interest payments are not well covered by EBIT. Despite an increase in debt-to-equity ratio over five years to 19.8%, the net debt level remains satisfactory at 13.5%. Earnings growth has accelerated by 143.6% over the past year compared to a decline over five years, yet return on equity is low at 0.4%.

• Click to explore a detailed breakdown of our findings in Crimson Wine Group's financial health report.
• Evaluate Crimson Wine Group's historical performance by accessing our past performance report.

Next Steps

• Navigate through the entire inventory of 326 US Penny Stocks here.
• Contemplating Other Strategies? The end of cancer? These 37 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com